dxOmics

We are excited to launch dxOmics at AGBT25 We offer support for the implementation of genome-diagnostics for cancer and rare diseases in clinics and genetic testing laboratories. We support a genomic data analysis workflow and clinical decision support system optimized for: - full genome interpretation ‘beyond the exome’ - integrative analysis of RNA-seq data - long-read genome sequencing - somatic variant interpretation for tumor therapy selection - liquid biopsy for treatment monitoring, MRD and relapse detection - comprehensive report generation - AI-diagnostics and automated re-analysis of cases - cloud-based and on-premises solutions With over 50,000 data sets analyzed, this clinically developed and evaluated decision support platform meets highest diagnostic standards for accuracy and efficacy in genetic testing and research of rare and oncological diseases. Meet the dxOmics Founders Dr. Tobias Haack (CMO) – Board certified in molecular and clinical geneticist, heading a diagnostic and research lab in translational genomics. Dr. Marc Sturm (CTO) – Bioinformatics and clinical genomics specialist, developing next-generation sequencing solutions. Dr. Stephan Ossowski (CSO) – Renowned genomics professor, pioneering AI-driven diagnostic research. Daniela Bezdan (CEO) – Business strategist and industry expert, driving dxOmics' growth and partnerships. We are actively looking for strategic partners, investors, and collaborators to help scale dxOmics and bring next-generation diagnostics to more patients worldwide. https://dxomics.de/